[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Benlysta (GlaxoSmithKline) providing insights into the drug market landscape and market forecast of Benlysta upto 2030. The report, titled “Benlysta (belimumab) – Market Size, Forecast, and Drug Insight – 2030” is now available for review and analysis.
Are you interested in finding out the projected market size of Benlysta in 2030? Click @ Benlysta Market Size
The Benlysta Market Report offers projected sales forecasts for Benlysta for indications until 2030, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
BENLYSTA Overview:
BENLYSTA (belimumab) is a fully-humanized monoclonal antibody administered through both intravenous and subcutaneous routes. This antibody effectively binds to and deactivates B-lymphocyte stimulator, a cytokine expressed by B-cell lineage cells. This cytokine is responsible for activating B cells, promoting their proliferation, and inducing differentiation. By inhibiting B-lymphocyte proliferation and differentiation, BENLYSTA becomes the first and only biologic approved for treating both systemic lupus erythematosus (SLE), a chronic autoimmune disease, and lupus nephritis (LN), the kidney inflammation associated with lupus.
Functioning as a BLyS-specific inhibitor, BENLYSTA hinders the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. Although it does not directly bind to B cells, BENLYSTA’s interaction with BLyS prevents the survival of B cells, including autoreactive ones. Additionally, it reduces the differentiation of B cells into plasma cells that produce immunoglobulins.
Do you know your drug’s competitive positioning against Benlysta? Download Report: Benlysta Market Dynamics
GlaxoSmithKline’s Benlysta is serving as a beacon of hope for the patients suffering from the Lupus Nephritis.
Benlysta (belimumab) is a human IgG1λ monoclonal antibody specific for B-lymphocyte stimulator (BLyS)-specific inhibitor specified for the treatment of adult active lupus nephritis patients as well as SLE patients aged 5 years and older, who are receiving standard therapy. In SLE it is indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive, SLE who are receiving standard therapy. It is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. It does not bind B cells directly, but by binding BLyS, it inhibits the survival of B cells, including autoreactive B cells, and helps reduce the differentiation of B cells into immunoglobulin-producing plasma cells.
Benlysta is provided as a lyophilized powder (120 mg or 400 mg) in a single-use vial for intravenous infusion and should be reconstituted and diluted by aseptic technique. The recommended dosage of Benlysta is 10 mg/kg at 2-week intervals for the first three doses and at 4-week intervals thereafter reconstitute, dilute and administer as an intravenous infusion only, for 1 h. The Benlysta intravenous formulation is licensed for use in over 70 countries worldwide, including the US, Japan, and EU countries. It may be administered as an intravenous infusion in patients aged 5 years and older or as a subcutaneous injection in patients aged 18 years and older.
Moreover, European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active LN in Europe.
The report extensively covers the details and developments related to Benlysta, capturing important highlights on developmental pipeline, regulatory status and special designations of Benlysta, route of administration, safety and efficacy details.
Benlysta Market Assessment
This Benlysta market report provides a detailed market assessment of Benlysta for Lupus Nephritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2030.
Benlysta Clinical Assessment
The Benlysta market report provides the clinical trials information of Benlysta for Lupus Nephritis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Benlysta Competitive Landscape
The Benlysta market report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Benlysta.
Benlysta Market Size in the US
A dedicated section of the report focuses on the expected market size of Benlysta for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.
What is a Benlysta Prescribed for?
Benlysta is prescribed for the treatment of Lupus Nephritis.
Request for Sample Report @ https://www.delveinsight.com/sample-request/benlysta-belimumab-drug-insight-market-forecast
Key Highlights of Benlysta:
Why you should buy Benlysta Market Report:
Related Reports By DelveInsight:
Lupus Nephritis Market
DelveInsight’s Lupus Nephritis Market Insights, Epidemiology, and Market Forecast 2032’ report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Lupus Nephritis Pipeline
DelveInsight’s, “Lupus Nephritis Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting
